CoNCERT Management

Roger D. Tung President and Chief Executive Officer Roger D. Tung, Ph.D. is our scientific founder and has served as our President and Chief Executive Officer and as a mem- ber of our board of directors since April 2006. Before Concert, Dr. Tung was a founding scientist at Vertex Pharmaceuticals, a pharmaceutical company, where he was employed from 1989 to 2005, most recently as its Vice President of Drug Dis- covery. Prior to Vertex, he held various positions at Merck, Sharp & Dohme Research Laboratories, a global healthcare pro- vider, and The Squibb Institute for Medicinal Chemistry. He also serves as a member of the University of Wisconsin- Madison School of Pharmacy’s Board of Visitors, faculty mentor in the MIT IMPACT program, and strategic advisor to Long- wood Founder’s Fund. Dr. Tung received a B.A. in Chemistry from Reed College and a Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison.

Marc Becker Chief Financial Officer Mr. Marc Becker has served as our Chief Financial Officer since January 2018. Prior to joining Concert, Mr. Becker served as Senior Vice President and Chief Financial Officer at CRISPR Therapeutics from February 2016 to September 2017. Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a biopharmaceutical from January 2012 to February 2016. Before rEVO, Mr. Becker spent 10 years at Corpora- tion, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s Renal and Endocrine business. He also serves on the Board of Directors of Food for Free, a non-profit organization in Cambridge, MA. Mr. Becker began his career in auditing and commercial lending for fi- nancial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.

James Chief Development Officer Dr. James Cassella has served as our Chief Development Officer since February 2015. Prior to joining Concert, Dr. Cassella had senior level roles in biopharmaceutical companies, including Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from June 2004 to January 2015. Prior to Alexza Pharmaceuticals, Dr. Cassella held various management positions at Neurogen Corporation, including Senior Vice President, Clinical Re- search and Development. Before joining the biotechnology industry, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella received his Ph.D. in Physiological Psychology from Dartmouth College, completed a post- doctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. in psy- chology from the University of New Haven.

Nancy Stuart Chief Operating Officer Ms. Nancy Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharma- ceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Scion Pharmaceuticals, Inc., a pharmaceuti- cal company, Vertex Pharmaceuticals, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by S.A. She currently serves as a General Board Member of the YMCA of Greater Boston, a non-profit charitable organization. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management.

Justine E. Koenigsberg Senior Vice President, Corporate Communications and Investor Relations Ms. Koenigsberg joined Concert in March 2008 and currently serves as Senior Vice President, Corporate Communications and Investor Relations. She has more than 22 years corporate communications and investor relations experience within the biotechnology industry. Prior to joining Concert she held senior communication roles at ViaCell, Inc. and Transkaryotic Therapies (TKT) where she developed and implemented a variety of communication strategies and managed their investor relations programs. Prior to TKT, she held communications positions at Vertex Pharmaceuticals. Ms. Koenigsberg is a member of the National Investors Relations Institute and served on the Board of Directors and as a Past-President of its Boston Chapter. She holds a B.S. in Business Administration from Northeastern University.

Concert Pharmaceuticals, Inc. │99 Hayden Avenue │ Suite 500 │ Lexington, MA 02421 │ 781.860.0045 │www.concertpharma.com Robert Silverman, J.D., Ph.D. Senior Vice President, Legal Affairs Dr. Silverman joined Concert in January 2007 and currently serves as Senior Vice President, Legal Affairs. He was our General Counsel from January 2007 to June 2017. Prior to joining Concert, he served in various legal related roles at Mil- lennium Pharmaceuticals, Inc., Vertex Pharmaceuticals, and FMC Corporation. Dr. Silverman received his J.D. from Rut- gers Law School. He began his career as a research chemist after postdoctoral training in organic chemistry at Stanford University. Dr. Silverman received a Ph.D. in organic chemistry from the University of New Mexico and a B.A. from Lehigh University. Since 2012, he has been on the Business Development Fundamentals faculty for BIO.

Virginia Braman Vice President, Clinical Development Ms. Braman joined Concert in April 2010 and currently serves as Vice President, Clinical Development. She has over 25 years of research, development and clinical experience. Prior to Concert, she had a variety of clinical roles across a num- ber of therapeutic areas at Cambridge BioScience, ImmunoGen, Cardiokine, and NitroMed. At NitroMed, she managed the Phase 3 clinical trial for BiDil® for the treatment of heart failure, which led to FDA approval. Prior to joining the bio- technology industry, Ms. Braman conducted research using monoclonal antibodies at both Beth Israel Hospital in Boston and University of Pennsylvania Medical School. Ms. Braman holds a B.S. in Biology from Northeastern University.

Christine Boisclair Vice President, Regulatory Affairs and Quality Assurance Ms. Boisclair joined Concert in June 2016 as Vice President, Regulatory Affairs and Quality Assurance with more than 30 years Regulatory Affairs experience in the biopharmaceutical industry and across multiple therapeutic areas. Prior to join- ing Concert, Ms. Boisclair was Vice President, Regulatory Affairs at Forum Pharmaceuticals. Before joining Forum Pharma- ceuticals Ms. Boisclair held management roles at several companies including Insmed Inc, Agennix Inc, OSI Pharmaceuti- cals Inc, Genzyme Corporation, Immulogic Pharmaceuticals and Parexel International. Ms. Boisclair began her regulatory career at Searle Pharmaceuticals and Glaxo in the UK. She received a Bachelor of Science Honors Degree in Biochemis- try from the University of York in the United Kingdom.

Cameron J. Cowden, Ph.D. Vice President, Pharmaceutical Development Dr. Cowden joined Concert in January 2016 and currently serves as Vice President, Pharmaceutical Development. He has nearly 20 years of process chemistry and chemical engineering experience in the pharmaceutical industry. Prior to join- ing Concert, Dr. Cowden was an Executive Director in Process Chemistry at Merck. He received his Ph.D. from the University of Melbourne, Australia and was a postdoctoral fellow at Cambridge University in the United Kingdom.

Julie Fields Liu, Ph.D. Vice President, Research and Development Management Dr. Liu joined Concert in January 2007 and currently serves as Vice President, Research and Development Management. She has more than 20 years of experience in the pharmaceutical and biotechnology industry in the fields of medicinal chemistry, research management, and development program management. Prior to joining Concert, Dr. Liu worked at Millennium Pharmaceuticals in the areas of oncology, inflammation, and metabolic disease. She earned her B.S. in Chem- istry with honors and distinction from the University of North Carolina at Chapel Hill, and her Ph.D. in Organic Chemistry from the University of California, Berkeley.

Scott Weintraub Vice President, Commercial and Product Strategy Mr. Weintraub has served as Vice President, Commercial and Product Strategy since August 2016. Mr. Weintraub has more than 20 years commercial experience, including strategic product assessment, brand positioning, commercial life cycle management and sales and marketing. Prior to joining Concert he was Vice President of Product Strategy and Mar- keting at Forum Pharmaceuticals. He also served as Senior Director of Marketing at Sunovion Pharmaceuticals and held sales and marketing positions at AstraZeneca. He holds a B.S. in Finance and Marketing from Florida State University and an MBA in Health Administration and Policy from University of Miami.

Concert Pharmaceuticals and the CoNCERT logo are trademarks of Concert Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. 2

January 2019